Indegene Limited IPO
Initial Public Offering for Indegene Limited Indegene Limited is a “digital-first” commercialization firm with a singular dedication to the life sciences sector worldwide. Solutions provided by the company help the biopharmaceutical, emerging biotech, and medical device industries create better products, bring them to market faster, and increase revenues throughout the product’s entire life cycle.
This is made possible by the company’s use of purpose-built technology with over two decades of experience in the healthcare industry. All areas of a life sciences business’ operations—commercial, medical, regulatory, and research, and development—are catered to by its suite of products. More than 70% of the company’s total revenue from continuing operations in each of the Fiscal Years 2022, 2021, and 2020 came from these 19 clients. These clients include 19 of the world’s 20 top biopharmaceutical companies by revenue in 2021.
As a company located at the crossroads of medicine and technology, we provide services throughout the entire pharmaceutical and medical device commercialization process. In addition to our Enterprise Medical Solutions and Enterprise Clinical Solutions, which focus on the medical and R&D needs of life sciences organisations, we also provide Enterprise Commercial Solutions and Omnichannel Activation solutions.
Issue Price, Date, News, Allotment Status & GMP
Updates for Indegene Limited IPO
Indegene Limited IPO Details:
| IPO Open Date | Not Available |
| IPO Close Date | Not Available |
| Listing Date | Not Available |
| Face Value | ₹2 per share |
| Price | Not Available |
| Lot Size | Not Available |
| Issue Size | Not Available |
| Fresh Issue | [●] shares
(aggregating up to ₹950 Cr) |
| Offer For Sale | 36,291,497 shares
(aggregating up to ₹[●] Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| QIB Shares Offered | Not more than 75% of the Offer |
| NII (HNI) Shares Offered | Not less than 15% of the Offer |
| Retail Shares Offered | Not less than 10% of the Offer |
IPO Solutions for Indegene Limited:
- Enterprise Commercial Solutions: Indegene Limited’s Enterprise Commercial Solutions mostly help life sciences companies with their digital marketing operations. In 2021, the most expensive part of running a life sciences business was sales and marketing. In this segment, service providers help life sciences companies make customized marketing plans and campaigns by making promotional content based on clinical trial data that has been approved. The company’s Enterprise Commercial Solutions help life sciences companies improve their scale efficiency and personalize their engagement strategies for healthcare professionals (“HCPs”), patients, and operations with the help of technology and analytics.
- Omnichannel Activation: Indegene Limited’s Omnichannel Activation solutions help life sciences companies use a “digital first” approach to optimize the last-mile promotion of biopharmaceutical products and medical devices to HCPs across multiple channels. In this case, the company takes on the role that has usually been done by medical representatives, who sell products to HCPs in person. But by using digital technologies and its own analytics, it hopes to get the same result more quickly and for less money. Emails, virtual sales reps, social media, and other digital platforms are some of the ways the company communicates.
- Enterprise Medical Solutions: As part of Enterprise Medical Solutions, Indegene Limited sets up “centers of excellence” (CoEs) to help its clients bring together large-scale regulatory and medical operations. CoEs are made up of teams of people from different fields who work on projects for one or more clients. Through these CoEs, the company helps with: I writing medical content, regulatory submissions, product labels, and other medical information; (ii) reviewing medical communications to make sure they follow regulatory guidelines and ethical practices; (iii) pharmacovigilance services, i.e., the monitoring and processing of adverse events caused by the use of biopharmaceutical products; and (iv) conducting “real-world evidence” (RWE) based medical research to improve patient care.
Indegene Limited IPO Financial Analysis:
| Particulars | 3M of FY-23(in cr.) | FY-22(in cr.) | FY-21(in cr.) | FY-20(in cr.) | CAGR |
| Revenue from Operations | 520.98 | 1664.61 | 966.27 | 642.93 | 37.3% |
| Other Income | 18.73 | 25.89 | 30.65 | 3.45 | |
| Employee Cost | 312.14 | 1014.34 | 535.60 | 369.92 | |
| Other expenses | 100.48 | 363.35 | 200.15 | 129.36 | |
| EBITDA | 127.08 | 312.81 | 261.18 | 147.10 | 28.6% |
| EBITDA margin% | 24.39% | 18.79% | 27.03% | 22.88% | |
| Depreciation | 9.80 | 33.45 | 25.55 | 19.34 | |
| Interest | 2.37 | 5.96 | 6.96 | 8.84 | |
| Share of (loss)/profit in an associate | 0.00 | 0.00 | -0.20 | 0.53 | |
| Exceptional items (net) | 0.00 | -46.90 | 2.99 | -43.66 | |
| PBT | 114.91 | 226.50 | 231.46 | 75.80 | 44.0% |
| Total tax | 29.09 | 63.68 | 45.78 | 26.12 | |
| PAT | 85.82 | 162.82 | 185.68 | 49.68 | 48.5% |
| PAT margin% | 16.47% | 9.78% | 19.22% | 7.73% |
Indegene Limited IPO Offer for Sale Details:
| S. No. | Name of the Selling Shareholder | Number of Equity Shares
being offered in the Offer for Sale (Up to) |
|
| 1. | Manish Gupta | 1,118,596 Equity Shares | |
| 2. | Dr. Rajesh Bhaskaran Nair | 383,818 Equity Shares | |
| 3. | Anita Nair | 1,151,454 Equity Shares | |
| 4. | Vida Trustees Private Limited (Trustee of Fig
Tree Trust) in its capacity as a partner of Group LifeSpring |
8,030,000 Equity Shares | |
| 5. | BPC Genesis Fund I SPV, Ltd | 5,545,093 Equity Shares | |
| 6. | BPC Genesis Fund I -A SPV, Ltd | 2,876,208 Equity Shares | |
| 7. | CA Dawn Investments | 17,186,328 Equity Shares | |
Indegene Limited IPO Revenue from Solutions:
| Segment | 3M of FY-23(in cr.) | % | FY-22(in cr.) | % | FY-21(in cr.) | % | FY-20(in cr.) | % | CAGR |
| Enterprise Commercial Solutions | 305.79 | 58.69% | 1016.16 | 61.04% | 564.58 | 58.43% | 343.77 | 53.47% | 71.9% |
| Omnichannel Activation | 60.94 | 11.70% | 141.42 | 8.50% | 78.74 | 8.15% | 61.36 | 9.54% | 51.8% |
| Enterprise Medical Solutions | 130.28 | 25.01% | 431.56 | 25.93% | 305.01 | 31.57% | 237.81 | 36.99% | 34.7% |
| others | 23.98 | 4.60% | 75.48 | 4.53% | 17.95 | 1.86% | N.A. | 0.00% | N.A. |
| Total | 520.99 | 100.00% | 1664.61 | 100.00% | 966.27 | 100.00% | 642.93 | 100.00% | 60.9% |
Indegene Limited IPO Offer for Sale Details:
| S. No. | Name of the Selling Shareholder | Number of Equity Shares
being offered in the Offer for Sale (Up to) |
|
| 1. | Manish Gupta | 1,118,596 Equity Shares | |
| 2. | Dr. Rajesh Bhaskaran Nair | 383,818 Equity Shares | |
| 3. | Anita Nair | 1,151,454 Equity Shares | |
| 4. | Vida Trustees Private Limited (Trustee of Fig
Tree Trust) in its capacity as a partner of Group LifeSpring |
8,030,000 Equity Shares | |
| 5. | BPC Genesis Fund I SPV, Ltd | 5,545,093 Equity Shares | |
| 6. | BPC Genesis Fund I -A SPV, Ltd | 2,876,208 Equity Shares | |
| 7. | CA Dawn Investments | 17,186,328 Equity Shares | |
Indegene Limited IPO Acquisitions:
| S. No. | Name of the acquired company/selling entity | Description of the acquired company | Geography served | Year and month of acquisition |
| 1 | Cult Health | A full-service healthcare marketing agency | North America | October 2022 |
| 2 | Medical Marketing Economics, LLC | Value-based pricing, market access, and reimbursement strategy firm | North America and Europe | August 2021 |
| 3 | DT Associates Limited | A digital transformation and customer experience (“CX”) consulting firm. | North America and Europe | August 2019 |
| 4 | Wincere, Inc. | A company providing clinical data management services. | North America | December 2016 |
| 5 | Encima Group, Inc. | A company offering marketing automation and analytics services. | North America | November 2016 |
| 6 | Skura Corporation Inc | A company offering omnichannel sales enablement software products. | North America | April 2016 |
| 7 | Vantage Point Healthcare Information Systems, Inc | A population health analytics platform | North America | October 2015 |
| 8 | Total Therapeutic Management, Inc | A healthcare quality improvement and clinician engagement business | North America | December 2013 |
| 9 | Aptilon Holdings, Inc. | A company engaged in building customer engagement technologies | North America | November 2012 |
| 10 | MedCases LLC | A company offering continuing medical education (“CME”) on digital platforms | North America | August 2006 |
| 11 | Medsn, Inc. | A biopharmaceutical sales training company | North America | September 2005 |
